Table 1.
Baseline characteristics of the cohort
| n = 3771 | |
|---|---|
| Gender, n (%) | |
| Male | 1039 (28) |
| Female | 2732 (72) |
| Age, mean (s.d.), years | 60 (12) |
| <55, n (%) | 1153 (31) |
| 55–64, n (%) | 1164 (31) |
| 65–74, n (%) | 1008 (29) |
| 75+, n (%) | 446 (12) |
| Ethnicity, n (%) | |
| White | 2866 (76) |
| Non-white | 74 (2) |
| Missing | 831 (22) |
| Country of residence, n (%) | |
| England | 3194 (85) |
| Northern Ireland | 372 (10) |
| Scotland | 161 (4) |
| Wales | 44 (1) |
| Smoking, n (%) | |
| Current | 892 (24) |
| Previous | 1497 (40) |
| Never | 1364 (36) |
| Missing | 18 (0) |
| Previous NHS-IC-reported cancer excluding NMSC and CIS, n (%) | 144 (4) |
| RA disease duration, median (IQR), years | 6 (1–15) |
| 0–3, n (%) | 1231 (33) |
| >3–10, n (%) | 1028 (27) |
| >10, n (%) | 1488 (39) |
| Missing, n (%) | 24 (1) |
| Disease activity, mean DAS28 (s.d.) | 5.1 (1.3) |
| Low (DAS28 <3.2), n (%) | 289 (8) |
| Moderate (DAS28 3.2–5.1), n (%) | 1551 (41) |
| High (DAS28 >5.1), n (%) | 1876 (50) |
| Missing, n (%) | 55 (1) |
| Disability, mean HAQ (s.d.) | 1.5 (0.8) |
| Low (HAQ 0–1), n (%) | 881 (23) |
| Moderate (HAQ >1–2), n (%) | 1346 (36) |
| High (HAQ >2–3), n (%) | 780 (21) |
| Missing, n (%) | 764 (20) |
| Median number of nbDMARDs ever received (IQR) | 2 (1–3) |
| Exposure to AZA, ciclosporin or CYC, n (%) | 367 (10) |
| Steroid exposure, n (%) | 853 (23) |
| NSAID exposure, n (%) | 2019 (54) |
NMSC: non-melanoma skin cancer.